Tuesday 13 October 2026 Export AUTL’s income statement to Excel — free account

Autolus Therapeutics PLC Sponsored ADR

In the quarter to June 2026, revenue grew 118.4%, EPS grew 16.7% and free cash flow grew 67.6%, each against the same quarter a year earlier.

1.63 0.11 −6.32%

Follow AUTL

Alert me

Market cap: $463.1M
P/E: 0.0×
Fwd P/E: −1.7×
Dividend yield: —
F-score: 3/9
Altman Z: −3.17
Beneish M: n/a
Dividend safety: n/a

Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

	Dec 25			Mar 26			Jun 26			Sep 26
Buy	—	—	—	—	—	—	—	—	—	—	—	—
Sell	—	—	—	—	—	—	—	—	—	—	—	—

Insider Ownership 9.63%

Capital & Financial Ratios $m

Market Cap 463.12

Revenue 117.39

Net Income (280.16)

Free Cash Flow (232.73)

Net Debt (125.40)

Current Ratio 4.89

Debt/Equity 1.04

P/E ratio 0.00

Fwd P/E (1.69)

P/S ratio 3.95

P/B ratio 6.19

Past 5Y EPS Growth —

This Y EPS Growth 27.48%

Next Y EPS Growth 20.13%

Next Y revenue growth 98.71%

Next 5Y EPS Growth 26.28%

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/Sales, ten years

P/S against its own 10 years 1.28%

10-year low 10-year high

P/B against its own 10 years 93.87%

10-year low 10-year high

EV/Sales against its own 10 years 13.62%

10-year low 10-year high

Dividends

Payout Ratio —

Annual Dividend Rate —

Annual Dividend Yield —

	total	individual payouts
2023	Powerpack
2022	Powerpack
2021	Powerpack

special payouts not included in total or ratios

Assets vs Liabilities $m

	2023	2024	2025	Q'26
Cash	240	589	302	203
Receivables	—	0	24	44
Inventory	—	4	33	33
Other	—	—	—	—
	275	661	436	336

	2023	2024	2025	Q'26
Payables	0	2	3	1
ST’ Debt	—	—	—	—
Other	—	4	10	13
	45	61	73	69

Compound Annual Growth %

	10y	5y	3y
Sales	—	113.11%	128.01%
Cash Flow	0.00%	0.00%	0.00%
Earnings	0.00%	0.00%	0.00%
Book Value	2.25%	(3.24%)	(15.83%)

Revenue $m

	Mar	Jun	Sep	Dec	Year
’26	26	46	—	—	—
’25	9	21	21	24	75
’24	10	—	—	0	10
’23	1	—	0	0	2
’22	0	—	2	4	6
’21	0	2	0	0	2
’20	0	0	1	0	2

Fiscal quarters ending in the months shown.

Operating Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(65)	(25)	—	—	—
’25	(76)	(73)	(68)	(67)	(284)
’24	(41)	(51)	(77)	(38)	(206)
’23	(42)	(38)	(40)	(25)	(146)
’22	(35)	(31)	(32)	(15)	(112)
’21	(37)	(37)	(35)	(9)	(118)
’20	(24)	(27)	(39)	(28)	(118)

Fiscal quarters ending in the months shown.

Free Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(68)	(26)	—	—	—
’25	(84)	(80)	(80)	(66)	(311)
’24	(41)	(52)	(86)	(62)	(241)
’23	(46)	(43)	(42)	(26)	(157)
’22	(36)	(33)	(39)	(15)	(123)
’21	(39)	(38)	(39)	(11)	(127)
’20	(27)	(29)	(43)	(33)	(132)

Fiscal quarters ending in the months shown.

EPS $

	Mar	Jun	Sep	Dec	Year
’26	(0.27)	(0.15)	—	—	—
’25	(0.26)	(0.18)	(0.30)	(0.34)	(1.08)
’24	(0.24)	(0.22)	(0.31)	(0.09)	(0.86)
’23	(0.23)	(0.26)	(0.26)	(0.44)	(1.20)
’22	(0.41)	(0.46)	(0.47)	(0.23)	(1.57)
’21	(0.53)	(0.47)	(0.47)	(0.51)	(1.97)
’20	(0.60)	(0.62)	(0.72)	(0.82)	(2.76)

Fiscal quarters ending in the months shown.

Group	Line	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026e
Price, $
Price, $	Low	—	—	19.17	9.50	3.00	4.60	1.60	1.61	2.07	1.11	Analyst estimates 2026–2028 Powerpack
	High	—	—	53.24	36.00	17.19	9.98	5.59	6.94	7.45	2.80
People
People	Employees	—	126	166	290	376	324	399	463	647	752
	Revenue/emp, $m	0.00	0.01	0.01	0.01	0.00	0.01	0.02	0.00	0.02	0.10
Income, $m
Income, $m	Revenue	2	2	1	3	2	2	6	2	10	75
	Gross margin, %	100.00	0.00	0.00	100.00	100.00	100.00	100.00	100.00	(12.52)	(27.83)
	EBT	(23)	(23)	(52)	(139)	(166)	(166)	(149)	(208)	(219)	(286)
	EBT margin, %	(1,380.98)	0.00	0.00	(4,780.19)	(9,694.29)	(7,123.95)	(2,335.96)	(12,273.38)	(2,165.36)	(378.78)
	Net income	0	20	0	(124)	(142)	(142)	(149)	(208)	(221)	(288)
	Depreciation	0	1	2	5	6	8	7	7	8	10
Per share, $
Per share, $	Revenue	0.04	0.00	0.00	0.07	0.03	0.03	0.07	0.01	0.04	0.28
	Earnings	(0.31)	(0.49)	(1.42)	(2.88)	(2.76)	(1.97)	(1.57)	(1.20)	(0.86)	(1.08)
	Cash flow	(0.25)	0.07	(1.00)	(2.36)	(2.28)	(1.64)	(1.18)	(0.84)	(0.81)	(1.07)
	Capex	0.00	(0.06)	0.00	(0.43)	(0.28)	(0.12)	(0.11)	(0.06)	(0.14)	(0.10)
	Free cash flow	(0.25)	0.01	(1.00)	(2.79)	(2.57)	(1.76)	(1.30)	(0.90)	(0.94)	(1.17)
	Book value	3.55	(0.08)	7.37	5.92	4.07	4.35	3.14	0.64	1.67	0.67
	Shares, m	40	51	32	43	52	72	95	174	255	266
Valuation, ×
Valuation, ×	P/E	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
	P/S	0.00	0.00	0.00	195.49	268.76	160.56	27.16	215.42	56.97	7.03
	P/B	5.05	5.05	4.70	2.23	2.19	1.19	0.59	10.67	1.40	2.97
	EV/Sales	0.00	0.00	0.00	130.93	208.41	34.33	(28.43)	180.58	5.68	3.90
	EV/FCF	0.00	0.00	(18.97)	(3.16)	(2.68)	(0.63)	1.50	(6.34)	(0.25)	(0.91)
Cash, $m
Cash, $m	Operating cash flow	(10)	3	(32)	(101)	(118)	(118)	(112)	(146)	(206)	(284)
	Capex	(2)	(3)	(10)	(19)	(15)	(9)	(11)	(11)	(35)	(27)
	Free cash flow	(10)	0	(32)	(120)	(132)	(127)	(123)	(157)	(241)	(311)
Balance, $m
Balance, $m	Working capital	137	0	212	224	163	318	379	231	600	362
	Total debt	—	0	0	24	51	17	19	48	50	—
	Net debt	(137)	(137)	(217)	(188)	(104)	(294)	(364)	(192)	(540)	(302)
	Shareholders’ equity	143	(4)	233	255	210	313	299	111	427	178
Returns, %
Returns, %	ROA	(13.27)	(58.09)	(16.97)	(44.41)	(47.54)	(40.61)	(33.23)	(48.14)	(38.11)	(41.92)
	ROIC	(83.69)	0.00	0.00	(136.01)	(98.66)	(537.42)	0.00	0.00	0.00	0.00
	ROE	(41.66)	(64.50)	(18.34)	(50.81)	(61.13)	(54.30)	(48.64)	(101.61)	(81.91)	(94.98)

Negative figures in brackets.

All 10 years →

Fiscal years to Dec 2025 · latest quarter Jun 2026 · fundamentals updated 28 Sep 2026

Charts ten years each

Company	Market cap	P/E	Fwd P/E	Revenue growth (Q)	EPS growth (Q)	FCF growth (Q)	Gross margin (Q)	EBIT margin (Q)	Compare
ARVN Arvinas, Inc.	$499.6M	57.3×	— (loss-making)	+1,014.73% (above 0%: growing)	n/m	+49.79% (above 0%: growing)	96.40%	65.72%	Compare
EPRX Eupraxia Pharmaceuticals Inc.	$491.7M	— (loss-making)	—	—	n/m	−56.41% (below 0%: shrinking)	—	0.00%	Compare
MPLT MapLight Therapeutics, Inc.	$490.7M	— (loss-making)	—	—	n/m	−31.91% (below 0%: shrinking)	—	0.00%	Compare
AUTL Autolus Therapeutics PLC Sponsored ADR	$481.8M	— (loss-making)	— (loss-making)	+118.37% (above 0%: growing)	n/m	+67.55% (above 0%: growing)	55.20%	(95.95%)
OVID Ovid Therapeutics	$480.4M	— (loss-making)	— (loss-making)	+463.85% (above 0%: growing)	n/m	−268.54% (below 0%: shrinking)	100.00%	(2,141.61%)	Compare
ASMB Assembly Biosciences, Inc.	$479.1M	22.3×	— (loss-making)	+38.94% (above 0%: growing)	n/m	+7.58% (above 0%: growing)	100.00%	(47.44%)	Compare
YDES YD Bio Limited	$476.8M	—	—	—	—	—	—	—	Compare
RZLT Rezolute, Inc.	$471.1M	— (loss-making)	—	—	n/m	+40.23% (above 0%: growing)	0.00%	0.00%	Compare
ENTX Entera Bio Ltd.	$462.4M	— (loss-making)	— (loss-making)	+200.00% (above 0%: growing)	n/m	−108.86% (below 0%: shrinking)	0.00%	0.00%	Compare
Median of peers	$479.8M	—	—	+331.93%	—	−31.91%	96.40%	0.00%

All 614 Biotechnology stocks →

Autolus Therapeutics PLC Sponsored ADR (AUTL) key facts

Autolus Therapeutics PLC Sponsored ADR (AUTL) is a Biotechnology company in the Healthcare sector, traded in the US as an ADR.
As of October 12, 2026, AUTL traded at $1.74, a market capitalization of $463.1 million.
Return on equity was −95.0% and debt-to-equity 1.04.
Its Piotroski F-score is 3 out of 9 and its Altman Z-score is −3.17 (distress zone) for fiscal 2025.

Source: company filings (standardised) and stockrow calculations · fundamentals updated Sep 28, 2026.